Monoclonal gammopathy: Natural history studied with a retrospective approach

Haematologica

Volumn 92, Issue 8, 2007, Pages 1131-1134

  Steingrimsdottir, Hlif ^a,b   Haraldsdottir, Vilhelmìna ^a   Olafsson, Ísleifur ^a   Gudnason, Vilmundur ^c   Ogmundsdottir, Helga M ^b,d  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b UNIVERSITY OF ICELAND   (Iceland)

^c ICELANDIC HEART ASSOCIATION   (Iceland)

^d ICELANDIC CANCER SOCIETY   (Iceland)

Author keywords

Monoclonal gammopathy of undetermined significance; Multiple myeloma; Natural history; Waldenst m's macroglobulinemia

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PARAPROTEIN;

ADULT; AGED; ANALYSIS; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOFIXATION; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PROTEIN ELECTROPHORESIS; SERUM; WALDENSTROEM MACROGLOBULINEMIA; BLOOD; DISEASE COURSE; FOLLOW UP; ICELAND; MIDDLE AGED; PARAPROTEINEMIA; PRECANCER; RETROSPECTIVE STUDY; TIME;

AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; ICELAND; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOMA PROTEINS; PARAPROTEINEMIAS; PARAPROTEINS; PRECANCEROUS CONDITIONS; RETROSPECTIVE STUDIES; TIME FACTORS; WALDENSTROM MACROGLOBULINEMIA;

EID: 35748969137     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11284     Document Type: Article

References (8)

1. Kyle RA, Therneau TM, Raikumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354:1362-9.
2. Blade J, Lopez-Guillermo A, Rozman C, Cervantes F, Salgado C, Aguilar JL, et al. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br J Haematol 1992;81:391-4.
3. Pasqualetti P, Casale R. Risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. Biomed Pharmacother 1997;51:74-8.
4. van de Poel MH, Coebergh JW, Hillen HF. Malignant transformation of monoclonal gammopathy of undetermined significance among out-patients of a community hospital in southeastern Netherlands. Br J Haematol 1995;91:121-5.
5. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564-9.
6. Gregersen H, Mellemkjaer L, Ibsen JS, Dahlerup JF, Thomassen L, Sorensen HT. The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. Haematologica 2001;86:1172-9.
7. Ogmundsdottir HM, Haraldsdottir V, G MJ, Olafsdottir G, Bjarnadottir K, Sigvaldason H, et al. Monoclonal gammopathy in Iceland: a population-based registry and follow-up. Br J Haematol 2002;118:166-73.
8. Jonsdottir LS, Sigfusson N, Sigvaldason H, Thorgeirsson G. Incidence and prevalence of recognised and unrecognised myocardial infarction in women. The Reykjavik Study. Eur Heart J 1998;19:1011-8.